Fig. 5∣. Anti-LILRB3 antibody inhibits human MDSC activity.

(a-b) Representative histogram of 31 patients with cancer (total of 76 patients with cancer) shows that anti-LILRB3 attenuates MDSC suppressive functions on CD4⁺ (a) and CD8⁺ (b) T-cell proliferation in some patients with cancer as determined by flow cytometry. (c-d) Quantification of 4 individual patient samples from proliferating human CD4⁺ (c) and CD8⁺ (d) T cells cocultured with autologous MDSCs selected for patients with >10% proliferation with anti-LILRB3. Wells were coated with human galectin-4 (20 μg/mL) and cocultured cells were treated with hIgG control or anti-LILRB3 (20 μg/mL). (e-f) Quantification of 4 individual patient samples from proliferating human CD4⁺ (e) and CD8⁺ (f) T cells cultured with autologous MDSCs selected for patients with >10% proliferation with anti-LILRB3. Wells were not coated with human galectin-4 and cocultured cells were treated with hIgG control or anti-LILRB3 (20 μg/mL). (g-h) Median fluorescence intensity (MFI) change in CD86, CD163, and CD206 for isolated MDSCs treated with hIgG control or anti-LILRB3 (20 μg/mL) in patient samples with melanoma (g) or lung cancer (h). One to three replicates were performed for each condition and one experiment was performed for each condition. Error bars represent SEM and * indicates two-tailed student’s t-test p < 0.05.